Literature DB >> 8422248

Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain.

F M Heemskerk1, H C Chen, F L Huang.   

Abstract

MARCKS is one of the major physiological substrates of PKC and was reported to be phosphorylated by PKC at 4 serine residues that are within the CaM-binding region (Graff et al., J. Biol. Chem. 264, 11912, 1989). Using MARCKS from rat brain and a synthetic peptide of 25 amino acids containing all 4 of the serine residues, we investigate the differences in phosphorylation by PKC isozymes I, II and III. Tryptic peptide analysis of PKC phosphorylated MARCKS or peptide, we found 32P was in peptides of (K)S152FK, (R)FS156FK and LS160GFS163FK. Further digestion of LSGFSFK with alpha-chymotrypsin revealed that 32P incorporation occurred only at Ser163 but not at Ser160. The initial rates and stoichiomatry of phosphorylation of Ser152 and Ser156 were twice as those of Ser163 using either one of the three PKC isozymes. These results indicate that in vitro, PKC phosphorylates MARCKS only at three sites, but not at Ser160 as that reported previously, and there was no preferential phosphorylation of MARCKS by either PKC isozyme I, II or III.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422248     DOI: 10.1006/bbrc.1993.1036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Involvement of protein kinase C-epsilon in activity-dependent potentiation of large dense-core vesicle exocytosis in chromaffin cells.

Authors:  Yong-Soo Park; Eun-Mi Hur; Bo-Hwa Choi; Eunyee Kwak; Dong-Jae Jun; Su-Jin Park; Kyong-Tai Kim
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

2.  Regulation of spinogenesis in mature Purkinje cells via mGluR/PKC-mediated phosphorylation of CaMKIIβ.

Authors:  Takeyuki Sugawara; Chihiro Hisatsune; Hiroyuki Miyamoto; Naoko Ogawa; Katsuhiko Mikoshiba
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

3.  Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Authors:  Colleen Carpenter; Alexander G Zestos; Rachel Altshuler; Roderick J Sorenson; Bipasha Guptaroy; Hollis D Showalter; Robert T Kennedy; Emily Jutkiewicz; Margaret E Gnegy
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

4.  Two myristoylated alanine-rich C-kinase substrate (MARCKS) paralogs are required for normal development in zebrafish.

Authors:  Laura E Ott; Zachary T McDowell; Poem M Turner; J McHugh Law; Kenneth B Adler; Jeffrey A Yoder; Samuel L Jones
Journal:  Anat Rec (Hoboken)       Date:  2011-08-01       Impact factor: 2.064

5.  INTRACELLULAR SIGNALING BY BILE ACIDS.

Authors:  Mohammed Sawkat Anwer
Journal:  J Biosci (Rajshari)       Date:  2012

Review 6.  Protein kinase C in IL-2 signal transduction.

Authors:  Y Lu; J P Durkin
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

7.  Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals.

Authors:  R Tremblay; B Chakravarthy; K Hewitt; J Tauskela; P Morley; T Atkinson; J P Durkin
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

8.  Taurolithocholate-induced MRP2 retrieval involves MARCKS phosphorylation by protein kinase Cϵ in HUH-NTCP Cells.

Authors:  Christopher M Schonhoff; Cynthia R L Webster; M Sawkat Anwer
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

Review 9.  Aberrant expression and functions of protocadherins in human malignant tumors.

Authors:  Ming Shan; Yonghui Su; Wenli Kang; Ruixin Gao; Xiaobo Li; Guoqiang Zhang
Journal:  Tumour Biol       Date:  2016-07-24

10.  Inactive membrane protein kinase Cs: a possible target for receptor signalling.

Authors:  B R Chakravarthy; J F Whitfield; J P Durkin
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.